海泰新光汪方华详解国际化布局，光学技术延伸医疗赛道

Core Insights - The company is adapting its global production capacity in response to evolving trade conditions between China and the U.S., focusing on optical technology as a core competency while expanding into the medical device sector [1][2]. Group 1: Company Strategy - The company has initiated the construction of a production base in Thailand and a small-scale production facility in the U.S. to mitigate the impact of tariffs, which have increased up to 100% on certain Chinese products [2]. - Since July 2023, the company has adjusted its supply chain by changing the shipping process to manage tariff costs more effectively, resulting in a price increase of 15%-20% for customers to cover additional costs [2]. - The Thai production base was strategically planned to comply with local value-added requirements, allowing the company to benefit from favorable tariff treatment for exports to the U.S. [2]. Group 2: Market Position and Financials - The company has established itself as a significant partner for U.S. clients, with 60%-70% of its revenue coming from the U.S. market, and anticipates an increase in export share over the next three to five years [2]. - The medical segment has a gross margin of approximately 65% and a net margin of up to 30%, indicating a stable and attractive return on investment [3]. - The company is focusing on surgical laparoscopic products while also expanding into medical analysis and testing products, leveraging its optical technology expertise [2][3]. Group 3: Future Investments - Future investments will concentrate on both optical and medical sectors, with an emphasis on a comprehensive product line in the medical field and long-term technological value in the optical domain [3]. - The company is also exploring AI applications in the medical field, developing products with AI-assisted diagnostic capabilities [3].